MARKHAM, ON, Oct. 15 /CNW/ - Cytochroma today announced that it has appointed John Cunningham, CVO, BM BCh, DM, FRCP, to the Company's Scientific Advisory Board.
Dr. Cunningham is Professor of Nephrology at the UCL Medical School, London and Consultant Nephrologist at the Royal Free Hospital, London. His early training was at Cambridge and Oxford Universities, with postgraduate training in The University of London and Washington University School of Medicine, St. Louis, USA. In 2005, he was appointed to the position of Physician to HM the Queen. Dr. Cunningham has extensive experience in the fields of hypertension, renal stone disease, acute and chronic kidney disease, renal transplantation and dialysis, and metabolic bone disease. He has published in excess of 100 peer reviewed scientific articles, is a visiting professor to various universities in Europe, Australia, and the United States, a member of numerous international expert panels and working groups, and a national and international lecturer.
"We are delighted and honored that Dr. Cunningham has agreed to advise Cytochroma on its efforts to develop new drugs for secondary hyperparathyroidism in chronic kidney disease patients," said Charles W. Bishop, Ph.D., President and Chief Executive Officer of Cytochroma. "Dr. Cunningham's wealth of knowledge and clinical experience will be invaluable as we move our products through mid- and late-stage clinical trials."
Other members of Cytochroma's Scientific Advisory Board include:
- Geoff Block, MD - Director of Clinical Research, Denver Nephrology
- David Allen Bushinsky, MD - Professor of Medicine and of Pharmacology
and Physiology, University of Rochester School of Medicine, and
Chief, Nephrology Division, University of Rochester Medical Center
- Russell Chesney, MD - Le Bonheur Professor and Chair, Department of
Pediatrics, University of Tennessee Health Science Center
- Bess Dawson-Hughes, MD - Professor of Medicine, Tufts University
School of Medicine, and Senior Scientist and Director, Bone
Metabolism Laboratory Jean Mayer USDA Human Nutrition Research Center
on Aging at Tufts University
- Glenville Jones, PhD - Head of Biochemistry Department, Professor of
Biochemistry & Medicine, Queen's University, Kingston, Ontario
- Kevin Martin, MD - Director of Research, Division of Nephrology, St.
Louis University School of Medicine
- L. Darryl Quarles, MD - Vice Chairman for Research, Department of
Internal Medicine, and Director, The Kidney Institute and Division of
Nephrology at the University of Kansas Medical Center
- Isidro Salusky, MD - Professor of Pediatric Medicine, David Geffen
School of Medicine, and Director of Clinical Research Center, UCLA
School of Medicine
- Stuart Sprague, MD - Professor of Medicine, Feinburg School of
Medicine, and Chief, Division of Nephrology & Hypertension, Evanston
Northwestern Healthcare, Northwestern University
Cytochroma is a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary products to treat and prevent the clinical consequences of vitamin D insufficiency and secondary hyperparathyroidism (SHPT) associated with chronic kidney disease (CKD). The Company specializes in developing new vitamin D therapies which are designed to safely and effectively treat patients with stage 3, 4 or 5 CKD. Cytochroma has three lead product candidates in clinical development for CKD patients: CTA018 Injection and CTAP201 Injection are being developed for the treatment of SHPT in stage 5 CKD, while CTAP101 Capsules are being developed for the treatment of vitamin D insufficiency and associated SHPT in stage 3 and 4 CKD. CTA018 Injection is being developed in partnership with Mitsubishi Tanabe Pharma Corporation for the U.S. and Asian markets, and Cytochroma retains co-promotion rights for this product in the U.S. In addition, Cytochroma is developing novel therapies to treat hyperphosphatemia in CKD patients.
For further information: For further information: about Cytochroma, please visit www.cytochroma.com. For information contact: Cytochroma Investors: Gordon Ngan, Executive Director, Corporate Development, Tel: (905) 479-5306 ext. 333, email@example.com; Cytochroma Media: Robert Stanislaro (FD), Tel: (212) 850-5657, firstname.lastname@example.org